Observational studyScientific reports2019
Prevalence and characterization of breakthrough pain in patients with cancer in Spain: the CARPE-DIO study.
Observational study in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Decoding Pancreatic Cancer Pain: From Tumor-Nerve Crosstalk to Targeted Analgesic Strategies.International journal of medical sciences · 2026Review
- A scoping review of breakthrough cancer pain: Multidimensional patient needs and influencing factors.Asia-Pacific journal of oncology nursing · 2025Review
- A Prospective, Single-Cohort, Open, Multi-center, Observational Study of Sublingual Fentanyl for Breakthrough Cancer Pain: Effectiveness, Safety, and Tolerability in Korean Cancer Patients.Cancer research and treatment · 2025Observational
- Validation of the Spanish Version of the Breakthrough Pain Assessment Tool in Patients With Cancer.Cureus · 2024Article
- Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control.BMC palliative care · 2024Article
- A rapid systematic review of breakthrough pain definitions and descriptions.British journal of pain · 2024Article
- Article
- Clinical relevance of deep learning models in predicting the onset timing of cancer pain exacerbation.Scientific reports · 2023Article
- Evaluation of Gabapentin as a Treatment of Breakthrough Cancer Pain Caused by Metastatic Prostate Adenocarcinoma.Journal of pain research · 2023Article
- Fentanyl in cancer pain management: avoiding hasty judgments and discerning its potential benefits.Drugs in context · 2023Review
- Breakthrough pain among cancer patients at oncology units in Northern Ethiopia; a multi-center study.Frontiers in oncology · 2023Article
- Retrospective Observational Study on the Characteristics of Pain and Associated Factors of Breakthrough Pain in AdvancedPain research & management · 2022Observational
- A Delphi Study on the Management of Neuropathic Cancer Pain in Spain: The DOLNEO Study.Journal of pain research · 2022Article
- Efficacy of adenosylmethionine combined with Si Mo Tang in treatment of neonatal jaundice.American journal of translational research · 2022Article
- Current management of cancer pain in Italy: Expert opinion paper.Open medicine (Warsaw, Poland) · 2022Review
- Pancreas Cancer-Associated Pain Management.The oncologist · 2021Review
- The Prevalence and Characteristics of Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.Cancers · 2021Article
- Patient Perspective on the Management of Cancer Pain in Spain.Journal of patient experience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to evaluate the prevalence, characteristics and impact of breakthrough pain (BTP) in patients with cancer attending the main specialties involved in the diagnosis and management of BTP in Spain using a multicenter, observational, cross-sectional, multidisciplinary study. Investigators had to record all patients seen at the clinic during 1 month, determine whether the patients had cancer pain, and apply the Davies algorithm to ascertain whether the patients were suffering from BTP. Of the 3,765 patients with cancer, 1,117 (30%) had cancer-related pain, and of these patients, 539 had BTP (48%, 95%CI:45-51). The highest prevalence was found in patients from palliative care (61%, 95%CI:54-68), and the lowest was found in those from hematology (25%, 95%CI:20-31). Prevalence varied also according to sex and type of tumor. According to the Alberta Breakthrough Pain Assessment Tool duration, timing, frequency, location, severity, quality, causes, and predictability of the BTP varied greatly among these patients. BTP was moderate (Brief Pain Inventory [BPI]-severity median score = 5.3), and pain interference was moderate (BPI-interference median score = 6.1) with a greater interference with normal work, general activity, and enjoyment of life. Patients with BTP showed a mean ± standard deviation score of 28.5 ± 8.0 and 36.9 ± 9.5 in the physical and mental component, respectively, of the SF-12 questionnaire. In conclusion, prevalence of BTP among patients exhibiting cancer-related pain is high. Clinical presentation is heterogeneous, and therefore, BTP cannot be considered as a single entity. However, uniformly BTP has an important impact on a patient's functionality, which supports the need for early detection and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.